Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Adaptive Biotechnologies Corp shares valued at $17,149 were sold by PISKEL KYLE on May 16 ’25. At $8.89 per share, PISKEL KYLE sold 1,929 shares. The insider’s holdings dropped to 277,396 shares worth approximately $2.9 million following the completion of this transaction.
Also, ROBINS HARLAN S sold 68,412 shares, netting a total of over 502,828 in proceeds. Following the sale of shares at $7.35 each, the insider now holds 1,279,524 shares.
Before that, Harlan Robins had added 68,412 shares to its account. In a trade valued at $503,512, the Officer bought Adaptive Biotechnologies Corp shares for $7.36 each.
As published in their initiating research note from Craig Hallum on June 18, 2025, Adaptive Biotechnologies Corp [ADPT] has been a Buy and the price target has been revised to $15. Analysts at Goldman upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late March. Earlier on January 05, 2023, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ADPT stock.
Analyzing ADPT Stock Performance
On last trading session,, Adaptive Biotechnologies Corp [NASDAQ: ADPT] rose 3.25% to $10.47. During the last five days, there has been a drop of approximately -1.51%. Over the course of the year, Adaptive Biotechnologies Corp shares have jumped approximately 74.65%. Shares of the company reached a 52-week high of $10.87 on 06/11/25 and a 52-week low of $5.96 on 01/02/25.
Support And Resistance Levels for Adaptive Biotechnologies Corp (ADPT)
According to the 24-hour chart, there is a support level at 10.11, which, if violated, would cause prices to drop to 9.75. In the upper region, resistance lies at 10.84. The next price resistance is at 11.20. RSI (Relative Strength Index) is 64.41 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Adaptive Biotechnologies Corp (ADPT)?
In terms of Adaptive Biotechnologies Corp share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 38.07% from the previous closing price of $10.14. Analysts anticipate Adaptive Biotechnologies Corp stock to reach 18 by 2025, with the lowest price target being 5. In spite of this, 11 analysts ranked Adaptive Biotechnologies Corp stock as Hold at the end of 2025. On December 21, 2022, Piper Sandler assigned a price target of “an Overweight” to the stock and upgraded coverage with a $14.
